Agios Pharmaceuticals Reports Financial Results for Q3 2025
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) has announced its third-quarter financial results, reflecting a continued commitment to delivering innovative treatments in rare diseases. The significant milestones achieved during this period highlight the potential of its flagship product, PYRUKYND (mitapivat), in addressing challenging medical needs.
Key Financial Highlights
For the third quarter of 2025, Agios reported net revenues amounting to $12.9 million from PYRUKYND. This marks an impressive 44% increase from the $9.0 million reported during the same period last year. Compared to the second quarter of 2025, where revenues were at $12.5 million, this 3% growth illustrates the company’s ongoing upward trajectory.
Patient Enrollment and Therapy Initiations
Agios has observed promising trends in patient engagement. The enrollment forms submitted by unique patients surpassed 262, demonstrating a 6% increase over the previous quarter. Of these, 149 patients are currently receiving therapy in the U.S., indicating a supportive environment for the adoption of PYRUKYND among healthcare professionals.
Regulatory Updates and Clinical Trials
The company is poised for important regulatory milestones related to PYRUKYND. The U.S. Food and Drug Administration (FDA) has set a new Prescription Drug User Fee Act (PDUFA) goal date of December 7, 2025, for the supplemental New Drug Application (sNDA) specifically addressing treatment for thalassemia patients. This extension was a response to the FDA's request for a Risk Evaluation and Mitigation Strategy (REMS), ensuring a thorough review process. Importantly, no new efficacy or safety data was requested, confirming the strength of previous submissions.
International Regulatory Advancements
In addition to U.S. progress, Agios has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), recommending approval of PYRUKYND for the treatment of anemia linked to both transfusion-dependent and non-transfusion-dependent thalassemia in adults. A final ruling from the European Commission is anticipated early in 2026.
Upcoming Trials and Strategic Initiatives
The RISE UP Phase 3 trial, focusing on the efficacy of mitapivat in sickle cell disease, is expected to release its topline results by the end of this year, with a potential U.S. commercial launch slated for 2026. Moreover, the enrollment for the Phase 2b tebapivat trial in lower-risk Myelodysplastic Syndromes (MDS) has been completed, with topline results expected in early 2026.
Financial Overview
As of September 30, 2025, Agios reported substantial liquidity with cash, cash equivalents, and marketable securities reaching $1.3 billion. This financial cushion is vital as the company prepares for upcoming commercial launches and continues to invest in its innovative pipeline aimed at rare diseases.
Management Insights and Commitment to Patients
Brian Goff, CEO of Agios, emphasized the company’s dedication to addressing the urgent needs within rare disease communities. 'We remain focused on our two key PYRUKYND milestones and the urgent need for innovation in the treatment of these serious diseases. Our commitment does not waver as we look to provide meaningful progress for patients in need.'
Frequently Asked Questions
What financial results did Agios Pharmaceuticals announce for Q3 2025?
Agios reported net revenues of $12.9 million for Q3 2025, a significant increase from previous quarters.
What are the upcoming regulatory milestones for PYRUKYND?
The FDA has set a PDUFA goal date of December 7, 2025, for PYRUKYND’s supplementary application for thalassemia treatment.
How has patient enrollment changed for PYRUKYND?
There was a 6% increase in unique patients completing prescription enrollment forms, totaling 262 in Q3 2025.
What are the upcoming clinical results expected from Agios?
Topline results from the RISE UP Phase 3 trial in sickle cell disease are anticipated by year-end 2025.
How does Agios plan to utilize its cash reserves?
Agios aims to use its $1.3 billion in cash for potential commercial launches and advancing its clinical programs.
